Amol Akhade: What’s new data coming up in PD-L1 negative advanced NSCLC?

Amol Akhade posted on LinkedIn:

“What’s new data coming up in PD-L1 negative advanced NSCLC?

Volrustomig, a monoclonal bispecific antibody, shows promising results in combination with chemotherapy for First-line mNSCLC. The phase 1b trial reveals good ORR and DCR in both non-Squamous and Squamous histology.

However, the trial also reports 7 treatment-related deaths, with two being immune-related adverse events. This highlights the importance of closely monitoring side effects in such treatment approaches.

PD-L1 negative advanced NSCLC remains an area with unmet needs, emphasizing the necessity for the development of newer molecules to address the challenges in this specific patient population.”

Source: Amol Akhade/LinkedIn

Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital.

He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant. Currently, he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.